Neil Singla, MD, Chief scientific Officer of Lotus Clinical Research, will chair the American Pain Society’s 2nd annual Conference on Analgesic Trials
Neil Singla, MD, Chief scientific Officer of Lotus Clinical Research, will chair the American Pain Society’s 2nd annual Conference on Analgesic Trials (APS-CAT) on May 17, 2017 in Pittsburgh, Pennsylvania, as a part of APS’ 36th Annual Scientific Meeting. The full-day session will discuss methods to optimize the complex process of analgesic drug development. We had over 200 pain researchers in attendance at the first event in 2016, discussing the design and conduct of analgesic clinical trials with an 8-member expert panel. Audience feedback was overwhelmingly positive.
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings, currently developing non-opioid products for the treatment of serious acute pain, today announced positive results from its second of two Phase III clinical trials evaluating intravenous (IV) meloxicam for the treatment of acute postoperative pain. In this trial, IV meloxicam achieved the primary endpoint of a statistically significant difference in Summed Pain Intensity Difference (SPID) over the first 24 hours (SPID24), compared to placebo, in patients following abdominoplasty surgery. With the positive data from this study, the Company believes this completes the efficacy program for the IV meloxicam New Drug Application (NDA)